Neonatal Opioid Withdrawal Syndrome (NOWS)


Neonatal Opioid Withdrawal Syndrome (NOWS), formerly known as Neonatal Abstinence Syndrome (NAS), refers to the collection of signs and symptoms that may occur in opioid-exposed newborns shortly after birth. Between 2010 and 2013, the number of infants with NOWS doubled with a total cost exceeding $23 million in Alabama.

The ALPQC aims to reduce variation in treatment and optimize the care of infants with NOWS through compassionate withdrawal treatment, with the goal of optimizing nonpharmacologic management, pharmacologic management, and providing a safe discharge for these infants and mothers.

To that end, we’ve developed a toolkit that utilizes evidence-based and standard practices used by other perinatal quality collaboratives. We recognize that each hospital is unique and not all of these factors need to be addressed in every facility. Therefore, it is important to use this toolkit to determine what might be relevant to your facility.

ALPQC initially introduced the NOWS initiative at its 2020 Annual Summit. The Summit agenda and slides can be found at the bottom of this page. The kickoff and onboarding for the NOWS Initiative will take place on January 27th, 2021.

ALPQC 2020 Summit Video and Slides

Have a Question?